ClinicalTrials.gg
TerminatedNCT00140140Updated Nov 26, 2019Results posted

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

A Phase 1/2 interventional study of ABI-007 and vinorelbine in Stage IV (Metastatic) Breast Cancer, sponsored by Celgene. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-26.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Unable to determine the optimum tolerated dose

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis — 2 open to participants now, 2 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Neoplasm Metastasis.

Enrollment
18th of 23
16 · median 56
Started
2005
with 1 other
Phase 1/2
3 of 23
none open now
Registered
5th of 23
by date
Lead sponsor
3 of 23
Celgene

Among the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, this one is the 18th largest by enrollment, is one of 2 that started in 2005, is one of 3 in phase 1/2, and was the 5th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

2 of the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor (G-CSF) (Patients with HER-2/neu positive disease may receive Herceptin, and 2) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the presence of planned growth factor support with G-CSF.

03

Conditions studied

  • Stage IV (Metastatic) Breast Cancer

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has microscopically confirmed invasive breast carcinoma with clinical and/or radiographic evidence of stage 4 disease. If diagnosis is based on pleural effusion, positive cytology must be confirmed.
  • Patient has had no prior chemotherapy for Stage 4 disease (hormone therapy is permitted). Prior adjuvant paclitaxel by 3-hour infusion is permitted, if there is no residual neuropathy. Prior adjuvant docetaxel on an every 3 week schedule is permitted.
  • Disease must be measurable (unidimensional by (RECIST) criteria) or evaluable (e.g., malignant effusion, marrow involvement). Elevated tumor markers alone are insufficient.
  • Age >18.
  • Southwest Oncology Group (SWOG)/Eastern Oncology Group () performance status must be \< or =2 at screen and on treatment day one.
  • must be estimated at >16 weeks.
  • Prior irradiation is permitted, provided:

    • Does not exceed 25% of the estimated bone marrow volume
    • Measurable/evaluable disease exists outside the radiation field, or progressive disease is documented within the radiation field.
  • must be obtained prior to registration.
  • Patients must be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis, spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or nitrosureas), or > 2 weeks from prior hormonal therapy.
  • All patients must have placement of appropriate central venous access device.
  • Tumor /neu expression must be determined prior to study enrollment. Assessment may be by fluorescence in situ hybridization (FISH) assay or by immunohistochemistry (ICC). If determination is intermediate by ICC, FISH must be performed. For enrollment purposes, this phase I study will not discriminate based on HER2 status. However, documentation of patients' HER2 status will be maintained and Herceptin will be prescribed for all HER2 positive patients.

Exclusion criteria

Exclusion Criteria:

  • Granulocytes \< 1,500/mm\^3.
  • \< 100,000/mm\^3.
  • \< 9 gm/dl.
  • Creatinine > 2.0 mg/dl.
  • Total > 2 mg/dl.
  • Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung .
  • Medically unstable as judged by the patient's physician.
  • Pregnancy or lactation; failure to employ adequate .
  • Uncontrolled central nervous system (CNS) disease.
  • Pre-existing Grade ≥ 2 peripheral neuropathy except for abnormalities due to cancer.
  • Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
  • Prior therapy with vinorelbine or prior therapy with a taxane that resulted in neuropathy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1: 80 mg ABI-007 + 15 mg vinorelbine

    Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.

    Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab

  • Experimental
    Part 2: 80 mg ABI-007 + 15 mg vinorelbine

    Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.

    Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab · Biological: G-CSF

  • Experimental
    Part 2: 90 mg ABI-007 + 20 mg vinorelbine

    Weekly intravenous infusion of 90 mg/m\^2 ABI-007, followed by an infusion of 20 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.

    Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab · Biological: G-CSF

Interventions

  • Weekly intravenous infusions over 30 minutes.

    Also known as: Abraxane®, Nab®-Paclitaxel, paclitaxel protein-bound particles for injectable suspension

  • Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.

    Also known as: Navelbine, vinorelbine tartrate, 5'noranhydrovinblastine

  • Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered. Trastuzumab is commercially available and was not supplied by the Sponsor.

    Also known as: Herceptin

  • BiologicalG-CSF

    During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines. In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg. G-CSF is commercially available and was not supplied by the Sponsor.

    Also known as: granulocyte-colony stimulating factor

06

What researchers measure

Primary outcomes

  1. Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

    Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.

    Time frame: up to month 30

  2. Participants With Dose Limiting Toxicities

    Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Any drug-related toxicities CTC Grade 3 or higher were considered dose limiting. Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death. Other conditions considered dose-limiting toxicities include: * requirement of a dose adjustment during the first 4 weeks * a dose delay of \>3 weeks during the first 4 weeks Grade 3 or greater toxicities attributed to the use of Herceptin were not considered dose-limiting toxicities. The optimal tolerated dose of ABI-007 and vinorelbine given concurrently was defined as the dose administered in the absence of DLTs.

    Time frame: up to month 1

  3. Percentage of Participants With Discontinued, Delayed or Interrupted Therapy

    Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.

    Time frame: up to week 129

  4. Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) blood counts were graded using NCI CTCAE version 3. ANC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 1.5\*10\^9/L; Grade 2 = \<1.5 - 1.0\*10\^9/L; Grade 3 = \<1.0 - 0.5\*10\^9/L; Grade 4 = \<0.5\*10\^9/L WBC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L Platelets: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L Hemoglobin: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100 g/L ; Grade 2 = \<100 - 80 g/L; Grade 3 = \<80 - 65 g/L; Grade 4 = \<65 g/L

    Time frame: up to week 129 (longest treatment)

  5. Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.

    Time frame: up to week 129 (longest treatment)

  6. Nadir Measurement for Hemoglobin (Hgb)

    Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.

    Time frame: up to week 129 (longest treatment)

Secondary outcomes

  1. Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

    Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

    Time frame: up to month 30

  2. Kaplan Meier Estimate for Time to Disease Progression (TTP)

    Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: up to month 30

  3. Kaplan-Meier Estimate for Duration of Response

    Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: up to month 30

  4. Kaplan Meier Estimate for Progression-Free Survival (PFS)

    PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Because no patients died as a result of a non-disease progression event, the analysis of PFS was identical to the analysis for TTP.

    Time frame: up to month 30

  5. Kaplan-Meier Estimates for Participant Survival

    Participant survival is the time from the first dose of study drug to participant death from any cause. Participants that did not die were censored at the last known time the participant was alive.

    Time frame: up to 39 months

07

Results

Posted Oct 24, 2013

Participant flow

Participant flow — Overall Study
MilestonePart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Started466
Completed244
Not completed222
Withdrew: Unacceptable toxicity112
Withdrew: Physician decision110

Outcome measures

PrimaryParticipants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.

Time frame:
up to month 30
Reported as:
Number · percentage of participants
Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
percentage of participantsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)25 (0.6 to 80.6)16.7 (0.4 to 64.1)33.3 (4.3 to 77.7)
PrimaryParticipants With Dose Limiting Toxicities

Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Any drug-related toxicities CTC Grade 3 or higher were considered dose limiting. Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death. Other conditions considered dose-limiting toxicities include: * requirement of a dose adjustment during the first 4 weeks * a dose delay of \>3 weeks during the first 4 weeks Grade 3 or greater toxicities attributed to the use of Herceptin were not considered dose-limiting toxicities. The optimal tolerated dose of ABI-007 and vinorelbine given concurrently was defined as the dose administered in the absence of DLTs.

Time frame:
up to month 1
Reported as:
Number · participants
Participants With Dose Limiting Toxicities
participantsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Participants With Dose Limiting Toxicities222
PrimaryPercentage of Participants With Discontinued, Delayed or Interrupted Therapy

Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.

Time frame:
up to week 129
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
percentage of participantsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
At least 1 ABI-007 dose reduction505017
At least 1 Vinorelbine dose reduction505017
At least 1 ABI-007 dose interruption000
At least 1 Vinorelbine dose interruption000
At least 1 therapy delay758367
PrimaryParticipant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) blood counts were graded using NCI CTCAE version 3. ANC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 1.5\*10\^9/L; Grade 2 = \<1.5 - 1.0\*10\^9/L; Grade 3 = \<1.0 - 0.5\*10\^9/L; Grade 4 = \<0.5\*10\^9/L WBC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L Platelets: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L Hemoglobin: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100 g/L ; Grade 2 = \<100 - 80 g/L; Grade 3 = \<80 - 65 g/L; Grade 4 = \<65 g/L

Time frame:
up to week 129 (longest treatment)
Reported as:
Number · participants
Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
participantsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
ANC: grade 0113
ANC: grade 1110
ANC: grade 2010
ANC: grade 3201
ANC: grade 4032
WBC: grade 0231
WBC: grade 1001
WBC: grade 2112
WBC: grade 3122
WBC: grade 4000
Platelets: grade 0446
Platelets: grade 1010
Platelets: grade 2010
Platelets: grade 3000
Platelets: grade 4000
Hemoglobin: grade 0010
Hemoglobin: grade 1200
Hemoglobin: grade 2134
Hemoglobin: grade 3122
Hemoglobin: grade 4000
PrimaryNadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.

Time frame:
up to week 129 (longest treatment)
Reported as:
Mean · 10^9/L
Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count
10^9/LPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
ANC1.74 ± 1.4441.00 ± 0.8641.72 ± 1.589
WBC2.79 ± 0.9992.56 ± 0.9622.92 ± 1.572
Platelets221.5 ± 108.19187.2 ± 70.35222.7 ± 50.11
PrimaryNadir Measurement for Hemoglobin (Hgb)

Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.

Time frame:
up to week 129 (longest treatment)
Reported as:
Mean · g/L
Nadir Measurement for Hemoglobin (Hgb)
g/LPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Nadir Measurement for Hemoglobin (Hgb)89.3 ± 16.1189.7 ± 14.5383.5 ± 6.09
SecondaryPercentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

Time frame:
up to month 30
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
percentage of participantsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Disease control7566.733.3
Complete response000
Partial response251733
Stable disease >=16 weeks50500
SecondaryKaplan Meier Estimate for Time to Disease Progression (TTP)

Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
up to month 30
Reported as:
Median · months
Kaplan Meier Estimate for Time to Disease Progression (TTP)
monthsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Kaplan Meier Estimate for Time to Disease Progression (TTP)8.8 (1.0 to 30.4)7.9 (3.5 to 16.4)4.2 (3.5 to 14.5)
SecondaryKaplan-Meier Estimate for Duration of Response

Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
up to month 30
Reported as:
Median · months
Kaplan-Meier Estimate for Duration of Response
monthsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Kaplan-Meier Estimate for Duration of Response10.47.99.6 (4.6 to 14.5)
SecondaryKaplan Meier Estimate for Progression-Free Survival (PFS)

PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Because no patients died as a result of a non-disease progression event, the analysis of PFS was identical to the analysis for TTP.

Time frame:
up to month 30
Reported as:
Median · months
Kaplan Meier Estimate for Progression-Free Survival (PFS)
monthsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Kaplan Meier Estimate for Progression-Free Survival (PFS)8.8 (1.0 to 30.4)7.9 (3.5 to 16.4)4.2 (3.5 to 14.5)
SecondaryKaplan-Meier Estimates for Participant Survival

Participant survival is the time from the first dose of study drug to participant death from any cause. Participants that did not die were censored at the last known time the participant was alive.

Time frame:
up to 39 months
Reported as:
Median · months
Kaplan-Meier Estimates for Participant Survival
monthsPart 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg Vinorelbine
Kaplan-Meier Estimates for Participant Survival32.7 (3.1 to 32.7)29.2 (25.2 to 29.2)22.2 (19.4 to 26.1)

Adverse events

Collected over Day 1 - up to 133 weeks (longest treatment plus 4 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg ABI-007 + 15 mg Vinorelbine—5/10 (50%)10/10 (100%)
90 mg ABI-007 + 20 mg Vinorelbine—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
Event80 mg ABI-007 + 15 mg Vinorelbine90 mg ABI-007 + 20 mg Vinorelbine
DyspnoeaRespiratory, thoracic and mediastinal disorders0/101/6
Febrile neutropeniaBlood and lymphatic system disorders1/100/6
BacteraemiaInfections and infestations1/100/6
Catheter related infectionInfections and infestations1/100/6
CellulitisInfections and infestations1/100/6
Cervical myelopathyNervous system disorders1/100/6
Facial nerve disorderNervous system disorders1/100/6
HydropneumothoraxRespiratory, thoracic and mediastinal disorders1/100/6
Most frequent other events
Showing 10 of 159
Most frequent other events
Event80 mg ABI-007 + 15 mg Vinorelbine90 mg ABI-007 + 20 mg Vinorelbine
AnemiaBlood and lymphatic system disorders8/106/6
FatigueGeneral disorders8/105/6
AlopeciaSkin and subcutaneous tissue disorders5/105/6
White blood cell count decreasedInvestigations8/103/6
HypoalbuminaemiaMetabolism and nutrition disorders8/102/6
Aspartate aminotransferase increasedInvestigations7/104/6
HypocalcaemiaMetabolism and nutrition disorders7/102/6
HypokalaemiaMetabolism and nutrition disorders7/102/6
Blood alkaline phosphatase increasedInvestigations5/104/6
RashSkin and subcutaneous tissue disorders6/104/6

Baseline characteristics

Age, Customized
Age, Customized(participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
< 65 years4 ± 5.745 ± 12.605 ± 12.2314
>= 65 years0112
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
Female46616
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
Asian1001
White, Non-Hispanic and Non-Latino35412
White, Hispanic or Latino0123
Menopausal Status
Menopausal Status(participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
Pre-menopausal1214
Post-menopausal34512
Smoking Status
Smoking Status(participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
Never Smoked2439
Current Smoker1102
Previous Smoker, but have Stopped1135
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Part 1: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 80 mg ABI-007 + 15 mg VinorelbinePart 2: 90 mg ABI-007 + 20 mg VinorelbineTotal
Status 0 (Asymptomatic)1214
Status 1 (Symptomatic but completely ambulatory)34411
Status 2 (Ambulatory but unable to work)0011
Status 3 (Limited self-care)0000
Status 4 (Completely disabled)0000
Status 5 (Death)0000
08

Study locations

2 sites
  • City of Hope Comprehensive Cancer Care Center
    Duarte, California 91010, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Aug 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Oct 24, 2013
Last update
Nov 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00140140
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Aug 2005
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Oct 24, 2013
Last update
Nov 26, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Vinorelbine

Start the discussion